Abstract CT162: Addition of parsaclisib (INCB050465), a PI3Kδ inhibitor, in patients with suboptimal response to ruxolitinib: A phase 2 study in patients with myelofibrosis
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Trials"
DOI: 10.1158/1538-7445.am2021-ct162
Abstract: Background: Ruxolitinib improves outcomes in patients (pts) with myelofibrosis (MF); however, suboptimal response may occur due to persistent PI3K/AKT pathway activation despite continued JAK inhibition. This phase 2 study (NCT02718300) evaluated optimal dosing and efficacy… read more here.
Keywords: response; study; ruxolitinib; parsaclisib ... See more keywords